Jefferies Starts Tango Therapeutics Inc. (TNGX) at Buy

Jefferies analyst Maury Raycroft initiates coverage on Tango Therapeutics Inc. (NASDAQ: TNGX) with a Buy rating and a price target of $19.00.

The analyst comments: "TNGX's lead assets '908 and '462 are both selective PRMT5-MTA inh for MTAP-del cancers, which are ~10-15% of all tumors. Currently in ph.I/II, brain-penetrant '908 is focused on GBM, while non-brain-penetrant '462 may have better efficacy vs competitors (based on preclin potency & selectivity) for other tumor types. Data update for both programs in 2H24 (we est same corp event) is a major de-risking event for TNGX. Initiate at Buy w/ $19 PT."

For an analyst ratings summary and ratings history on Tango Therapeutics Inc. click here. For more ratings news on Tango Therapeutics Inc. click here.

Shares of Tango Therapeutics Inc. closed at $9.84 yesterday.

You May Also Be Interested In

• Trump: Iran Will Pay For US Forces Killings Many Times Over
• Goldman Sachs on IREN Ltd. (IREN): 'We estimate that the newly announced contracts represent an additional ~$1 bn'
• Morgan Stanley Downgrades National Retail Properties (NNN) to Equalweight, 'Thesis Played Out'